The human body changes with age. That's not controversial, it's biology. After 40, glomerular filtration rate declines, insulin sensitivity decreases, prostate tissue grows, and lipid metabolism shifts. These changes happen whether you use AAS or not. The problem is that AAS and aging hit the same markers, and without age-specific reference ranges, you cannot tell normal aging from a genuine health signal.
After 40, six key markers shift in predictable ways. AAS modifies those shifts, and the real challenge is telling expected pharmacology apart from real pathology.
eGFR and Creatinine: Aging + AAS = Confusion
eGFR naturally declines by approximately 1 mL/min/1.73m² per year after age 40. This means a healthy 45-year-old athlete has an eGFR of about 85 to 95, not the 110+ they had at 25. Add AAS to the equation (increased creatinine from muscle mass and training), and the calculated eGFR can easily drop into the 70s or even 60s, values that technically read as "stage 2 chronic kidney disease.
Consider a concrete scenario: a 48-year-old bodybuilder, 95 kg at 12% body fat, trains legs the day before bloodwork. His creatinine is 1.4 mg/dL, giving an eGFR of 68 via CKD-EPI. His cystatin C is 0.9 mg/L, giving an eGFR of 92. That 24-point discrepancy is entirely muscle and training artifact. If the licensed medical professional reviewing his labs only sees the creatinine-based number, he might be told to stop the TRT or get a renal ultrasound ordered. The correct move is to repeat the creatinine after 48 hours of rest and low-protein intake, and to use cystatin C as the tiebreaker. A meaningful share of AAS users over 40 have a creatinine-based eGFR that reads well below their true kidney function for exactly this reason. Do not let a single elevated creatinine derail your protocol without this validation.
The problem is that eGFR equations (CKD-EPI, MDRD) include creatinine, which is influenced by muscle mass, diet, and training. A 45-year-old with 90 kg of lean mass and a recent training session will have a significantly lower calculated eGFR than their true kidney function. Cystatin C is the confirmatory marker here. It is not affected by muscle mass and provides a true read of kidney function.
When to Use Cystatin C
PSA and Prostate Health: Age-Adjusted Ranges
Prostate-specific antigen (PSA) rises with age, even in men without prostate pathology. The upper limit of normal at 40 is 2.5 ng/mL. At 50, it is 3.5 ng/mL. At 60, it is 4.5 ng/mL. AAS can raise PSA by stimulating prostate epithelium, a direct androgen effect that is not necessarily a sign of cancer.
When you're trying to tell apart a benign AAS-driven PSA bump from something pathological, two metrics matter most: PSA velocity, where a rise of more than 0.75 ng/mL per year warrants investigation, and free PSA ratio, where below 25% is suspicious and below 10% is highly concerning. If you've got a single elevated PSA with stable velocity and a normal free PSA ratio, that's likely just the AAS doing its thing.
PSA Above 4.0 Requires Investigation
HbA1c and Insulin Resistance: The Age-Amplifier Effect
Age is the strongest independent risk factor for insulin resistance. After 40, your muscle cells become less sensitive to insulin, your pancreatic beta-cell function declines, and your liver becomes more prone to gluconeogenesis. These changes are gradual but cumulative, and AAS accelerates them.
Fasting insulin and HOMA-IR are more sensitive than HbA1c for catching early insulin resistance in AAS users. HbA1c reflects average glucose over 3 months, but it can lag behind acute changes. A 45-year-old on 600 mg of testosterone enanthate with a fasting glucose of 95 mg/dL and fasting insulin of 18 µIU/mL has a HOMA-IR of 4.2, which is clearly insulin resistant, even though his HbA1c is 5.4%. The AAS-induced increase in muscle mass can initially improve glucose disposal, but the concurrent increase in visceral fat and hepatic gluconeogenesis eventually wins. Adding fasting insulin to your twice-yearly bloodwork is worth doing. If HOMA-IR is above 2.5, diet is the first lever to pull yourself; metformin and GLP-1 agonists are effective options too, but they're prescription medications, so starting one is a decision for a licensed medical professional, not something to add on your own.
A HbA1c of 5.6% at age 25 is borderline, not alarming. At 45 on AAS, the same number carries more weight because the trajectory points toward progressive decline. An AAS user over 40 whose HbA1c moves from 5.2 to 5.5 to 5.7% across 18 months is showing a metabolic pattern that will not self-correct.
HbA1c on AAS: The Threshold Shifts
Lipid Changes: The Youth Buffer Is Gone
In your 20s, your cardiovascular system has significant reserve. HDL naturally declines with age, roughly 1 to 2 mg/dL per decade, while LDL rises. AAS amplifies both trends. The net effect is that a lipid panel that looked "not great but acceptable" at 25 becomes genuinely concerning at 45. Not because the compounds changed, but because the baseline shifted.
Non-HDL cholesterol is a better target than LDL alone, especially after 40. It captures all atherogenic particles, including VLDL and IDL, which AAS can elevate. A 45-year-old with an LDL of 130 mg/dL and triglycerides of 200 mg/dL has a non-HDL of 180 mg/dL, which is high risk. The standard LDL calculation (Friedewald) becomes inaccurate when triglycerides are above 400 mg/dL, which can happen on orals. Use the direct LDL or apolipoprotein B measurement instead. ApoB is the number of atherogenic particles, and it is the best predictor of cardiovascular events. For AAS users over 40, a reasonable target is ApoB below 80 mg/dL, tighter than the general population target of 100. If your ApoB is above 90, that's worth bringing to a licensed medical professional or lipid specialist — statins alone may not fully overcome the AAS-induced lipid shift, and options like ezetimibe or a PCSK9 inhibitor are prescription decisions, not something to self-direct.
ApoB becomes even more important as a risk marker after 40. The ApoB/ApoA1 ratio typically increases with age due to declining ApoA1 production. When AAS suppress ApoA1 further (via HDL reduction), the ratio can shift dramatically. An ApoB/ApoA1 ratio above 1.0 after 40 carries more clinical weight than the same ratio at 25.
Bone Markers and Thyroid: The Silent Shifters
AAS protecting bone density is one of the most underappreciated benefits of the compounds. That said, they don't stop the clock on everything. Age-related shifts in vitamin D metabolism, calcium absorption, and PTH regulation still happen regardless of what you're running. If you're a man over 40, get your vitamin D checked annually and keep it above 50 nmol/L. Same goes for calcium, but make sure it's corrected for albumin so you're not chasing a misleading number. This matters even more if you train indoors or you're in the middle of winter, when sun exposure drops to nearly nothing.
TSH naturally rises with age. A TSH of 3.5 mIU/L at 55 is not the same signal as a TSH of 3.5 at 25; it may be normal aging of the pituitary-thyroid axis. However, AAS-induced TBG suppression can lower measured total T4, creating the appearance of hypothyroidism when free T4 is actually normal. Always confirm with free T4 before considering thyroid medication.
How Markers Shift: Age 25 vs. 45
| Marker | Age 25 | Age 45 |
|---|---|---|
| eGFR (CKD-EPI) | 105–120 | 80–100 |
| PSA | 0.3–1.5 ng/mL | 0.5–2.5 ng/mL |
| HbA1c | 4.8–5.2% | 5.0–5.6% |
| HDL (natural) | 45–60 mg/dL | 40–55 mg/dL |
| TSH | 0.5–3.0 mIU/L | 0.5–3.5 mIU/L |
| Vitamin D | 40–80 nmol/L | 35–70 nmol/L |
How Markers Shift: Age 45 vs. 55
| Marker | Age 45 | Age 55 |
|---|---|---|
| eGFR (CKD-EPI) | 80–100 | 70–90 |
| PSA | 0.5–2.5 ng/mL | 1.0–3.5 ng/mL |
| HbA1c | 5.0–5.6% | 5.2–5.8% |
| HDL (natural) | 40–55 mg/dL | 38–52 mg/dL |
| TSH | 0.5–3.5 mIU/L | 0.5–4.0 mIU/L |
| Vitamin D | 35–70 nmol/L | 30–65 nmol/L |
The Over-40 Bloodwork Protocol
If you're over 40 and using AAS, your monitoring protocol has to include these age-specific additions:
- Get an annual PSA with a free PSA ratio, and start this at 40, not 50.
- Get a Cystatin C at least once to validate your eGFR, and repeat it if your creatinine-based eGFR drops below 75.
- Get your HbA1c every 6 months so you catch the trend before it crosses 5.7%.
- Get your ApoB and Lp(a) measured annually, this gives you an age-adjusted cardiovascular risk assessment that actually tracks changes over time rather than relying on a single snapshot.
- Your annual bone health screen checks Vitamin D, calcium (corrected), PTH together, since these three work as a unit for bone metabolism.
- Get your TSH + free T4 checked annually, and if TSH comes back abnormal, pull the free T4 to confirm what's actually going on.
The most important principle is to never compare your results to a 25-year-old's reference ranges. Age-specific interpretation is not optional; it is essential for distinguishing normal aging from actionable pathology. An eGFR of 80 at 45 is not kidney disease. A PSA of 2.5 at 50 is not prostate cancer by itself. But both deserve trend monitoring and confirmatory testing when they accelerate.